Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]
Passage Bio, Inc. (PASG)
Company Research
Source: Yahoo! Finance
Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comparability of a high-productivity, suspension-based PBFT02 manufacturing process On track to obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026 Cash runway into 1Q 2027 PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent business highlights. “We are pleased to report that we have opened enrollment in our third FTD- GRN and first FTD- C9orf72 patient cohorts in our ongoing upliFT-D clinical trial of PBFT02. We recognize the urgent need for the development of disease-modifying therapies for the FTD patient community, and we remain focused on advancing our study expeditiously,” said Will Chou, M.D., president a
Show less
Read more
Impact Snapshot
Event Time:
PASG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PASG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PASG alerts
High impacting Passage Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PASG
News
- Passage Bio (NASDAQ:PASG) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Passage Bio (NASDAQ:PASG) had its price target raised by analysts at Chardan Capital from $6.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
- Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business HighlightsGlobeNewswire
- Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceGlobeNewswire
- Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference [Yahoo! Finance]Yahoo! Finance
PASG
Earnings
- 11/10/25 - Beat
PASG
Analyst Actions
- 11/12/25 - Chardan Capital
PASG
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- PASG's page on the SEC website